Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China

Lung cancer causes significant morbidity and mortality in China and worldwide. In China, lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for approximately 80%–85% of all lung cancer cases. Immunoth...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Anwen Xiong, Jiali Wang, Caicun Zhou
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
Accès en ligne:https://doaj.org/article/85401136b19c4d6bb7c8f3bf245ae86f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!